YAN LU1,2,#, KANG WANG3,#, YUANHONG PENG3,4, MENG CHEN5, LIN ZHONG3,4, LUJI HUANG3,4, FU CHENG3,4, XINDAN SHENG4,6, XIN YANG4,6, MANZHAO OUYANG3,4, GEORGE A. CALIN5,*, ZHIWEI HE1,*
Oncology Research, Vol.33, No.1, pp. 103-121, 2025, DOI:10.32604/or.2024.057472
- 20 December 2024
Abstract Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear. Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases. MicroRNAs were selected using the… More >
Login
Register
